Andrea De Giglio

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study

Antonio Tursi, Giovanni Brandimarte, Alfredo Papa et al. · The American Journal of Gastroenterology · 2010 · 491 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti et al. · Journal for ImmunoTherapy of Cancer · 2019 · 415 citations · Full text

Medicine, Immunology, Oncology +16

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

Biagio Ricciuti, Carlo Genova, Andrea De Giglio et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 362 citations · Full text

Medicine, Immunology, Oncology +16

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Hamzah Abu‐Sbeih, Faisal S. Ali, Abdul Rafeh Naqash et al. · Journal of Clinical Oncology · 2019 · 197 citations · Full text

Life Sciences, Immunology, Oncology +17

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Elena Verzoni, Giacomo Cartenì, Enrico Cortesi et al. · Journal for ImmunoTherapy of Cancer · 2019 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17